Navigation Links
Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
Date:9/3/2012

SEATTLE, Sept. 4, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today appointed former  Managing Director and Head of West Coast Biotechnology for Oppenheimer & Co. and its U.S. predecessor, CIBC World Markets, Matthew J. Plunkett, Ph.D., as CTI's Executive Vice President, Corporate Development. Dr. Plunkett will lead CTI's partnering strategy including development collaborations, licensing agreements, and strategic alliances.

Dr. Plunkett has more than 15 years' experience in the biopharmaceutical industry. This includes 9 years at Oppenheimer & Co. and CIBC World Markets.  Dr. Plunkett advised on more than 70 completed transactions companies in the U.S., Europe and Australia, including more than $4 billion in equity and equity-linked transactions and $1 billion in merger, acquisition and other financial advisory transactions.

Most recently, Dr. Plunkett was Chief Financial Officer at the California Institute for Regenerative Medicine, a $3 billion fund for California stem cell research. He also served as Vice President and Chief Financial Officer at iPierian, a privately-held development-stage biotechnology company. He began his scientific career at Sunesis Pharmaceuticals and Axys Advanced Technologies. Dr. Plunkett received a doctorate in Organic Chemistry from the University of California, Berkeley, and a bachelor of science in Chemistry from Harvey Mudd College, Claremont, California.

"Matt has a wealth of experience in financing, mergers, acquisitions and technology/market assessments," said James A. Bianco, M.D., President & CEO of CTI.

"CTI is one of a select few companies that both have the opportunity of a product approved in Europe, and drug candidates with attractive commercial potential for different blood-related cancers," Dr. Plunkett said. "It is all the more impressive that CTI has been able to establish this pipeline during a time of unprecedented challenges for the biotech industry. I look forward to contributing to CTI's success with value-creating transactions."

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

Media Contact:

Dan Eramian
T: 206.272.4343
C: 206.854.1200
E: deramian@ctiseattle.com
www.CellTherapeutics.com/press_room

Investors Contact:

Ed Bell
T: 206.282.7100
F: 206.272.4434
E: invest@ctiseattle.com
www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
3. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
4. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
5. Pro-Dex, Inc. Appoints Michael J. Berthelot Chief Executive Officer
6. Nephros Appoints John C. Houghton as President and Chief Executive Officer
7. Elsevier Appoints New President of Elsevier CPM Resource Center
8. GenWay Biotech Appoints New Vice President of Custom/OEM
9. Angeion Appoints Matthew S. Margolies as Executive Vice President - Global Sales
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Research and Markets has announced the addition of ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
(Date:2/21/2017)... DUBLIN , Feb. 21, 2017 Research and ... and Strategies - 2016" report to their offering. ... The latest research Anthrax Drugs Price Analysis ... global Anthrax market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Anthrax market? ...
(Date:2/20/2017)... , Feb. 20, 2017 Provides understanding ... and agreements entered into by the worlds leading ... https://www.reportbuyer.com/product/3605699/ Description The Global Renal Failure ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been ... to surgery, treatment, therapy and management. Regular exercise in proper environments has been ... despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... coverage in veterinary medicine, will be launching its first bi-monthly issue of 2017 ... medicine, business and practice management, and One Health. , In making the ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to ... backed by giants including Accenture, GE Ventures, and Software AG , will ...
(Date:2/21/2017)... , ... February 21, 2017 , ... A February 6 ... gastric balloons for weight loss. It found that the treatments have led to significant ... patients, when compared to unassisted efforts. It also noted very few problematic results relating ...
(Date:2/20/2017)... Ill. (PRWEB) , ... February 20, 2017 , ... ... to reduce the rate at which women are called back for additional examinations ... journal Radiology . , In 2011, the U.S. Food and Drug Administration ...
Breaking Medicine News(10 mins):